1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol hydrochloride

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s